Phaseline

Companies › Ensem Therapeutics

Ensem Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ETX-636
Pan-mutant-selective PI3Kα inhibitor and degrader
PIK3CAPhase 1Advanced Solid TumorsJun 2027
ETX-929
pan-KRAS inhibitor
KRASPhase 1Metastatic Colorectal Cancer (CRC)Oct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06993844ETX-636Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07912593ETX-929Phase 1Metastatic Colorectal Cancer (CRC)OncologyOct 2028

Targets

PIK3CA (1) KRAS (1)

Companies with the same targets

Eli Lilly Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Roche Novartis Quanta Therapeutics Vividion Therapeutics Bristol-Myers Squibb Amgen Astellas

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.